Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success

Download Whitepaper

Health

Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success

March 16, 2022

Asia

Gerard Dunleavy
Gerard Dunleavy

Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success

March 16, 2022

Asia

Gerard Dunleavy
Gerard Dunleavy
Gerard Dunleavy

Senior Consultant, Economist Impact, Health Policy Team

Gerard is a Senior Consultant with Economist Impact’s Health Policy team. He manages global engagements with international clients in the healthcare sector, from conceptualising to delivering and executing customised research projects. He manages multidisciplinary teams, conducting quantitative and qualitative analyses across various disease areas and health policies.
 
Prior to joining Economist Impact, Gerard worked in academic settings specialising in evidence-based synthesis and epidemiological studies. He holds a PhD in Public Health and Epidemiology and a Masters degree in Health Education and Promotion, both from Maastricht University.
Read more from Gerard Dunleavy

‘Asia Pacific’s Healthcare Technologies Ecosystem: Enhancing start-up and SME success’ is a whitepaper, written by Economist Impact, and commissioned by Medtronic in support of the EDB. The report details the current state of the Health and Medical Technologies (MedTech) sector in the Asia Pacific region, identifies the challenges for early-stage start-ups and small and mid-size enterprises (SMEs), and considers steps that can be taken to support this strategically important and growing market. 

The report is based on a quantitative survey of 150 executives, including C-suite and board members, from MedTech companies across 15 markets in the Asia-Pacific region, and the insights are supplemented by qualitative interviews with six healthcare leaders in the region. 

  • Finding the right talent is the most significant challenge for the healthcare technology sector. Most respondents (84%) agree or strongly agree that talent recruitment is the most significant challenge for early-stage start-ups. Support with recruitment and upskilling also ranked as the most important type of support start-ups/SMEs need to reach their next strategic milestone. Whether that support comes from government or private organisation programmes, or a mixture of both, strategies and pathways to attract talented graduates and executives to the healthcare technology sector are needed to support future growth.

  • A more cohesive partnership and collaboration ecosystem needs to be developed with greater integration across multiple stakeholders. Over 75% of respondents identified partnerships and collaborations with government, industry, and other technology innovators as a significant challenge for early-stage startups, ranking it third highest of all challenges. A further 65% rated the role of partnerships with health system stakeholders like industry groups, government and other companies as very important to their organisation’s success. Healthcare technology requires cross-domain collaborations and building support networks that facilitate collaboration could have a sizeable impact on innovation.

  • Government support is identified as a critical factor to foster healthcare technology sector innovation. Almost 40% of respondents identify better government support as the highest-ranked factor that would best support innovation in the market. Considering their own organisation’s trajectory, 29% of executives view government support targeted towards innovation or start-ups as the third most critical factor to help their organisation reach its next strategic milestone.

  • There is a gap between the patient/disease pathways that healthcare technology companies are investing in, and what they believe are the greatest unmet patient/disease needs. This could be from a lack of information sharing, whether between private and public sectors or within the sectors themselves, that distorts market signals, or perhaps the comparative profitability of sectors. Any market failure like this indicates a need for government intervention, while private companies could also collaborate on how to improve information sharing. 

  • The covid-19 pandemic has removed multiple institutional and cultural barriers to adoption of digital solutions in the healthcare technology setting, although some remain. Digitisation has grown far more rapidly than was previously thought possible and ushered in an acceptance of remote medical products and services, and alternative care models. It has fostered greater industry innovation—while 35% of respondents said the pandemic had resulted in the stagnation or demise of an idea, 55% said that it had enabled innovative ideas to come to fruition.

  • Data security should be a future focus for healthcare technology companies. Data security is a global and inter-sectoral issue, and over 45% of respondents ranked data security as the most significant barrier to the delivery of patient healthcare. Despite the magnitude of the challenge, data security could prove to be a lucrative opportunity for existing companies or those considering entering the healthcare technology sector.

Economist Impact would like to thank the participants of the survey and the interviewees who generously offered their time and insights, in particular:

  • Lalitha Bhaskara, Vice President, SAP.iO Foundries Asia Pacific Japan & China

  • Dr Keren Priyadarshini, Regional Business Lead, Worldwide Health,Microsoft Asia

  • Jean-Luc Butel, Board Member, Novo A/S, Rani Therapeutics, Takeda Pharmaceutical, SGInnovate, and former Executive Vice-President, Group President International Medtronic

  • Bronwyn Le Grice, CEO and Managing Director, Australian digital health commercialisation organisation, ANDHealth

In addition, Economist Impact would like to thank the following contributors who shared knowledge and insights and provided additional context to the findings:

  • Dr Loke Wai Chiong, Head (Integrated Health Promotion), Clinical Director (Programmes), MOH Office for Healthcare Transformation

  • Jonathan Ley, Assistant Director of InHealth and Finance Redesign, MOH Office for Healthcare Transformation

Download Whitepaper

Related content

17885

Health

Value-based healthcare in Sweden: Reaching the next level

The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.

These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit. 

This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.

Read more

Health

Breast cancer patients and survivors in the Asia-Pacific workforce

With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?

This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.
Read more

Health

The Cost of Silence

Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.

As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.

To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.

Download the report to learn more.

Read more

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week

Copyright © The Economist Newspaper Limited 2024. All rights reserved.